期刊文献+

超声导引下艾迪注射液及顺铂联合应用治疗恶性胸腔积液 被引量:4

Minimal-trauma tube installation guided under ultrasonography in treatment of malignant thoracic by intrapleural injection of Aidi and Cisplatin
下载PDF
导出
摘要 目的:比较艾迪注射液和顺铂及两者联用对恶性胸腔积液的治疗作用。方法:自2003年10月~2008年5月我院肿瘤科收治恶性胸腔积液患者149例,随机分为A、B、C3组,3组均超声引导下介入穿刺置入中心静脉导管,充分引流后,A组51例,胸腔注入艾迪注射液和顺铂;B组49例,胸腔内注入顺铂;C组49例胸腔内注入艾迪注射液。均每周1次,治疗1~4次不等。结果:有效率(RR),A、B、C3组分别为:82.4%、49%、55%,A组高于C组和B组,差异具有统计学意义(P〈0.05)。生存质量KPS评分有效率;A组高于C组和B组(P〈0.05)。毒性评价(U级以上):B组〉A组〉C组。三组两两比较差异有统计学意义(P〈0.05)。结论:艾迪注射液联合顺铂疗效优于单用顺铂或艾迪注射液,艾迪注射液优于顺铂。 Objective:To compare the therapeutical effect among Aidi injection ,Cisplatin and Aidi injection associated with Cisplantin for malignant pleural effusions therapy. Methods: From Oct. 2003 to May 2008,149 patients underwent malignant pleural effusion were randomly divided into three groups: A group (51cases),B group (49cases) and C group (49cases). All the three groups underwent ultrasound-guided central venous catheter closed drainage. Once a week, with thoroughly drainage, Aidi injection associated with Cisplatin, Cisplatin, Aidi injection was respectively injected into pleural cavity of A, B, C group. Resuits: As to cure rate,there was statistically difference ( P 〈0.05) among group A (82.4%) ,B(49%) and C(55%). According to survival quality KPS: A〉C( P d0.05)and C〉B( P 〈0.05). According to toxicity evaluation (above Ⅱ), there was also statistically difference ( P 〈0.05) among A,B and C (A〉B〉C). Conclusion: Aidi injection associated with Cisplatin is superior to solitary used Aidi injection or Cisplatin,and the efficacy of Aidi injection is superior to Cisplatin.
作者 孙凤芝
出处 《中国中西医结合影像学杂志》 2009年第5期338-341,共4页 Chinese Imaging Journal of Integrated Traditional and Western Medicine
关键词 超声 导引 中心静脉导管 恶性胸腔积液 艾迪注射液 顺氯氨铂 Interventional ultrasound Guidance Central venous catheter Malignant pleural effusions Aidi injection Cisplatin
  • 相关文献

参考文献6

二级参考文献12

  • 1崔京远,马红,崔秋娟,周东风,林惠忠.力尔凡联合顺铂对恶性腹腔积液临床疗效及端粒酶活性的影响[J].中国现代普通外科进展,2006,9(5):293-295. 被引量:1
  • 2赵家美 廖美琳 等.沙培林对癌性胸腔积液的疗效观察[J].中华结核和呼吸杂志,1994,(17):161-161.
  • 3Postmus PE, Brambilla E, Chansky K. The IASLC Lung Cancer Staging Project:proposals for revision of the M descriptors in the forthcoming ( seventh ) edition of the TNM classification of lung cancer [ J ]. J Thorac Onco1,2007,2 ( 8 ) :686 - 693.
  • 4韩宝惠.现代呼吸病治疗学[M].北京:人民军医出版社,2002:503-510.
  • 5Light RW, Erozan YS, Ball WC. Ceils in pleural fluid: their value in differential diagnosis [ J ]. Arch Intern Med, 1973,132 : 857 - 860.
  • 6Rusch VW, Harper GR. Pleural effusions in patients with malignancy//Roth JA, Ruckdeschel JC, Weisenburger TH, et al. Thoracic oncology[ M ]. Philadelphia : WB Saunders, 1989:594 - 598.
  • 7Marel M,Anustova M, Stasny B,et al. Incidence of plerual effusion in a well-defined region: epidemiologic study in central bohemia [ J ]. Chest, 1993,104 : 1486 - 1489.
  • 8Monte SA, Ehya H, Long WT. Positive effusion cytology as the initial presentation of malignancy [ J ]. Acta Cytol, 1987,31 : 448 - 452.
  • 9Katano M, Morisaki T. The past, present and future of the OK-432 therapy for patienls with malignant effusions [J]. Anticancer Res, 1998, 18(50):3917-3925.
  • 10殷宪淼,李梅林.国产药物治疗恶性胸腔积液的现状[J].肿瘤防治杂志,2001,8(6):686-688. 被引量:3

共引文献189

同被引文献85

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部